Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 123

Results For "ABLE"

4654 News Found

Merck to acquire life science company Mirus Bio for US$ 600 million
News | May 23, 2024

Merck to acquire life science company Mirus Bio for US$ 600 million

Acquisition will advance Merck’s integrated offering for viral vector manufacturing


AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
News | May 22, 2024

AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs


Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili
Drug Approval | May 21, 2024

Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States


ASG opens its branch of super-specialty eye hospitals in Noida
Healthcare | May 21, 2024

ASG opens its branch of super-specialty eye hospitals in Noida

ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad


Modular ATP study of the mCRM System meets primary safety and efficacy endpoints
Diagnostic Center | May 21, 2024

Modular ATP study of the mCRM System meets primary safety and efficacy endpoints

Additional data from APPRAISE ATP trial reinforce modular therapy approach


IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital
Startup | May 20, 2024

IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital

The collaboration aims to bolster healthcare entrepreneurship


Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19
Diagnostic Center | May 20, 2024

Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19

SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients


Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
Diagnostic Center | May 20, 2024

Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA

95.7% of patients responded to Breyanzi in the TRANSCEND FL trial


Glenmark launches next phase of ‘India First Heart First’ campaign
Healthcare | May 17, 2024

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases